GLP-1 is a gut hormone released after meals. Agonists imitate the signal: slower gastric emptying, glucose-dependent insulin, satiety signaling in the brain.
Slower gastric emptying — part of the pharmacology.
Glucose-dependent stimulation of β-cells.
Signal to hypothalamic satiety centers.
Suppression of glucagon release.
Semaglutide — GLP-1 only (one target). Tirzepatide — GIP+GLP-1 (two targets). Retatrutide — GIP+GLP-1+GCG (three targets). More targets mean stronger effects and more side-effect data.
Half-lives: semaglutide ~165 h, tirzepatide ~120 h, retatrutide ~6 days.
No, it is a separate hormone. Insulin is only one pathway it touches.
Three targets instead of one. More targets = more effect and more uncertainty.